Balyasny Asset Management
PALI icon

Balyasny Asset Management’s Palisade Bio PALI Stock Holding History

Balyasny Asset Management’s Portfolio PALI Stock Details PALI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.72M Buy
3,270,845
+2,945,478
+905% +$5.36M 0.01% 1309
2025
Q4 		$765K Buy
+325,367
New +$625K ﹤0.01% 2319

Other funds holding PALI

Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
BGI
B Group Inc Dallas, Texas $135M AUM 80% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Balyasny Asset Management's PALI Position: Q1 2026 in Review

Balyasny Asset Management increased its Palisade Bio (PALI) stake by 905% in Q1 2026, buying an estimated $5.36M and bringing the position to 3,270,845 shares worth $5.72M. The position accounts for 0.01% of the portfolio, ranked #1309.

Balyasny Asset Management first reported a position in PALI in Q4 2025 and has held it in 2 quarters since. 96 funds tracked by Wall St. Rank hold PALI as of Q1 2026.

  • Balyasny Asset Management held 3,270,845 shares of Palisade Bio worth $5.72M as of Q1 2026.
  • Balyasny Asset Management bought 2,945,478 Palisade Bio shares in Q1 2026, an estimated $5.36M.
  • Palisade Bio made up 0.01% of Balyasny Asset Management's portfolio in Q1 2026, its #1309 holding.
  • Balyasny Asset Management first reported a position in Palisade Bio in Q4 2025 and has held it in 2 quarters since.
  • 96 funds tracked by Wall St. Rank held Palisade Bio as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.